What is The Oncology Institute, Inc.'s repayments on advances?

The Oncology Institute, Inc. (TOI) reported repayments on advances of $882K in Q1 2026.

How has The Oncology Institute, Inc.'s repayments on advances changed year-over-year?

The Oncology Institute, Inc.'s repayments on advances decreased by 72.4% year-over-year, from $3.2M to $882K.

Revenue$147.4M+41.2%

Operating income-$6.5M+34.3%

Net income-$2.5M+87.3%

EPS (diluted)-$0.02+90.5%

Cash & equivalents$30.3M-23.8%

Total debt$104.9M+2.5%

Total equity-$16.3M-421%

Total assets$168.2M+2.6%

Operating cash flow-$2.2M+55.6%

CapEx$1.0M+218%

Free cash flow-$3.3M+38.7%

Market cap$511.91M+133%

Enterprise value$586.58M+108%

P/S0.9×+0.4×

Operating margin-6%-2.1pp

Net margin-8%-2.7pp

FCF margin-5.1%—

Return on equity-277.6%-700pp

Debt / equity20.2×+17.3×

Current ratio1.5×-0.3×

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept toi:RepaymentsOnAdvances.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is The Oncology Institute, Inc.'s repayments on advances?: The Oncology Institute, Inc. (TOI) reported repayments on advances of $882K in Q1 2026.
How has The Oncology Institute, Inc.'s repayments on advances changed year-over-year?: The Oncology Institute, Inc.'s repayments on advances decreased by 72.4% year-over-year, from $3.2M to $882K.